Safety, pharmacokinetics, and preliminary efficacy of E6201 in patients with advanced solid tumours, including melanoma: results of a phase 1 study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Safety, pharmacokinetics, and preliminary efficacy of E6201 in patients with advanced solid tumours, including melanoma: results of a phase 1 study

Published:2018-06 Issue:12 Volume:118 Page:1580-1585
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Tibes Raoul,Borad Mitesh J.,Dutcus Corina E.,Reyderman Larisa,Feit Kevie,Eisen Andrew,Verbel David A.,Von Hoff Daniel D.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/s41416-018-0099-5.pdf

Reference19 articles.

1. Friday, B. B. & Adjei, A. A. Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy. Clin. Cancer Res. 14, 342–346 (2008).

2. Wallace, E. M., Lyssikatos, J. P., Yeh, T., Winkler, J. D. & Koch, K. Progress towards therapeutic small molecule MEK inhibitors for use in cancer therapy. Curr. Top. Med Chem. 5, 215–229 (2005).

3. Davies, H. et al. Mutations of the BRAF gene in human cancer. Nature 417, 949–954 (2002).

4. Tiacci, E. et al. BRAF mutations in hairy-cell leukemia. N. Engl. J. Med. 364, 2305–2315 (2011).

5. Mercer, K. et al. Expression of endogenous oncogenic V600EB-raf induces proliferation and developmental defects in mice and transformation of primary fibroblasts. Cancer Res. 65, 11493–11500 (2005).

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular Targeting of the BRAF Proto-Oncogene/Mitogen-Activated Protein Kinase (MAPK) Pathway across Cancers;International Journal of Molecular Sciences;2024-01-03

2. Fungal Drug Discovery for Chronic Disease: History, New Discoveries and New Approaches;Biomolecules;2023-06-14

3. Systematic in vitro analysis of therapy resistance in glioblastoma cell lines by integration of clonogenic survival data with multi-level molecular data;Radiation Oncology;2023-03-11

4. Discovery of a Novel ATP-Competitive MEK Inhibitor DS03090629 that Overcomes Resistance Conferred by BRAF Overexpression in BRAF-Mutated Melanoma;Molecular Cancer Therapeutics;2023-01-09

5. Emerging Studies of Melanoma Brain Metastasis;Current Oncology Reports;2022-02-25

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3